Adverse event profile and associated factors following surgical voluntary medical male circumcision in two regions of Namibia, 2015-2018.
Adolescent
Adult
Aftercare
Age Factors
Child
Circumcision, Male
/ adverse effects
Cross-Sectional Studies
HIV Infections
/ prevention & control
Humans
Logistic Models
Male
Namibia
Postoperative Complications
/ epidemiology
Urologic Surgical Procedures, Male
/ adverse effects
Voluntary Programs
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
06
2021
accepted:
30
09
2021
entrez:
20
10
2021
pubmed:
21
10
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Monitoring clinical safety of voluntary medical male circumcision (VMMC) is critical to minimize risk as VMMC programs for HIV prevention are scaled. This cross-sectional analysis describes the adverse event (AE) profile of a large-scale, routine VMMC program and identifies factors associated with the development, severity, and timing of AEs to provide recommendations for program quality improvement. From 2015-2018 there were 28,990 circumcisions performed in International Training and Education Center for Health (I-TECH) supported regions of Namibia in collaboration with the Ministry of Health and Social Services. Two routine follow-up visits after VMMC were scheduled to identify clients with AEs. Summary statistics were used to describe characteristics of all VMMC clients and the subset who experienced an AE. We used chi-square tests to evaluate associations between AE timing, patient age, and other patient and AE characteristics. We used a logistic regression model to explore associations between patient characteristics and AE severity. Of the 498 clients with AEs (AE rate of 1.7%), 40 (8%) occurred ≤2 days, 262 (53%) occurred 3-7 days, 161 (32%) between day 8 and 14, and 35 (7%) were ≥15 days post-VMMC. Early AEs (on or before day 2) tended to be severe and categorized as bleeding, while infections were the most common AEs occurring later (p<0.001). Younger clients (aged 10-14 years) experienced more infections, whereas older clients experienced more bleeding (p<0.001). Almost 40% of AEs occurred after the second follow-up visit, of which 179 (91%) were infections. Improvements in pre-surgical and post-surgical counselling and post-operative educational materials encouraging clients to seek care at any time, adoption of alternative follow-up methods, and the addition of a third follow-up visit may improve outcomes for patients. Enhancing post-surgical counselling and emphasizing wound care for younger VMMC clients and their caregivers could help mitigate elevated risk of infection.
Identifiants
pubmed: 34669709
doi: 10.1371/journal.pone.0258611
pii: PONE-D-21-20649
pmc: PMC8528325
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0258611Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Infect Dis. 2018 Apr 3;66(suppl_3):S161-S165
pubmed: 29617774
PLoS One. 2015 Sep 25;10(9):e0138755
pubmed: 26405786
J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):16-23
pubmed: 31809358
PLoS One. 2013 May 22;8(5):e63134
pubmed: 23717402
BMC Health Serv Res. 2019 Nov 21;19(1):855
pubmed: 31752838
PLoS One. 2017 Nov 14;12(11):e0186831
pubmed: 29136009
Glob Health Sci Pract. 2014 Jan 09;2(1):93-102
pubmed: 25276565
PLoS One. 2018 Sep 27;13(9):e0205113
pubmed: 30261043
J Int AIDS Soc. 2014 Nov 17;17:19275
pubmed: 25406951
Bull World Health Organ. 2012 Oct 1;90(10):773-81
pubmed: 23109745
BMC Health Serv Res. 2016 Feb 17;16:61
pubmed: 26888178
PLoS One. 2014 Aug 21;9(8):e100008
pubmed: 25144194
Clin Infect Dis. 2018 Apr 3;66(suppl_3):S189-S197
pubmed: 29617779
PLoS One. 2019 Jun 10;14(6):e0218137
pubmed: 31181096
PLoS One. 2017 Nov 7;12(11):e0185904
pubmed: 29112959
J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1:S49-55
pubmed: 27331590
MMWR Morb Mortal Wkly Rep. 2013 Nov 29;62(47):953-7
pubmed: 24280914
Lancet. 2007 Feb 24;369(9562):657-66
pubmed: 17321311
PLoS One. 2015 Sep 14;10(9):e0137376
pubmed: 26367187
PLoS One. 2014 May 01;9(5):e95357
pubmed: 24788898
Clin Infect Dis. 2018 Apr 3;66(suppl_3):S198-S204
pubmed: 29617772
PLoS Med. 2005 Nov;2(11):e298
pubmed: 16231970
Lancet. 2007 Feb 24;369(9562):643-56
pubmed: 17321310
Clin Infect Dis. 2018 Apr 3;66(suppl_3):S229-S235
pubmed: 29617777
J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1:S43-8
pubmed: 27331589
J Acquir Immune Defic Syndr. 2015 May 1;69(1):e13-23
pubmed: 25942466
PLoS One. 2014 Jan 28;9(1):e86631
pubmed: 24489754
Clin Infect Dis. 2018 Apr 3;66(suppl_3):S173-S182
pubmed: 29617775
AIDS. 2017 Jul 1;31 Suppl 3:S233-S241
pubmed: 28665881
J Int AIDS Soc. 2019 Jul;22(7):e25369
pubmed: 31368235